Meeting
2023 ASCO Annual Meeting
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.
Authors
Rasmus Mikiver
University of Linköping, Linköping, Sweden
Rasmus Mikiver , Roger Olofsson Bagge , Michael A. Marchetti , Alexander Christopher Jonathan Van Akkooi , Daniel G. Coit , Christian Ingvar , Karolin Isaksson , Richard A. Scolyer , John Thompson , Alexander Varey , Johan Lyth , Edmund Bartlett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9571)
DOI
10.1200/JCO.2023.41.16_suppl.9571
Abstract #
9571
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
First Author: Robert Stassen
Poster
2024 ASCO Annual Meeting
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.
First Author: Hayley Marie Dunlop
Poster
2023 ASCO Quality Care Symposium
Interdisciplinary implementation of a synoptic reporting template for melanoma nodal surveillance ultrasound.
First Author: Kelsey B. Montgomery
Poster
2023 ASCO Annual Meeting
Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.
First Author: Manan Shah